Newron Pharmaceuticals S.p.A.
NWPHF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 2.25 | -0.09 | 0.17 |
| FCF Yield | -5.14% | -5.35% | -3.96% | -5.52% |
| EV / EBITDA | 6.40 | -27.17 | -21.50 | -33.56 |
| Quality | ||||
| ROIC | 51.52% | -38.97% | -37.82% | -21.01% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -0.28 | 0.92 | 0.49 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 70.03% | 10.80% | 11.05% | 22.43% |
| Free Cash Flow Growth | 0.49% | -94.60% | 19.09% | -2.56% |
| Safety | ||||
| Net Debt / EBITDA | 1.30 | -5.40 | -5.77 | -9.36 |
| Interest Coverage | 7.78 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 79.57 | 66.36 | 63.91 | 33.19 |